Navigation Links
Mother Nature's oral antibiotics research gets $2.25 million help from NIH
Date:10/3/2011

Research from Case Western Reserve University School of Dental Medicine to study an isolated agent from common oral bacteria may hold the answer as to how human beta defensins (HBDs)nature's way of keeping oral microbes from entering the body and wreaking havoc with our healthcan be used to create new treatments to block bacteria from entering through the epithelial linings on and in the body.

Aaron Weinberg, professor and chair of the department of biological sciences at the Dental School, will lead the research group on a five-year, $2.25 million National Institutes of Health-funded project.

The new grant, Weinberg said, will continue the exploration of their discovery last year of an agent called Fusobacterium nucleatum-associated Beta-Defensin Inducer (FAD-I).

This agent triggers the expression and release of the HBD peptides from epithelial cells that make up the mucosal linings of the body, such as skin, the respiratory track and the gastrointestinal and urogenital tracks.

Weinberg and his research group reported FAD-I's discovery in the Journal of Biological Chemistry article, "Fusobacterium nucleatum-Associated Beta-Defensin Inducer (FAD-I)." The researchers described the identification, isolation and functions of FAD-I.

The new grant that continues FAD-I research has several foci: (1) isolating which strains of F. nucleatum bacteria have more potent FAD-I activity and why, (2) continued research to understand more about the biology and structure of FAD-I, and (3) using a mouse model to see how effective it is as a potential treatment.

In addition, the researchers are particularly interested in why FAD-I sets defensins to work without triggering inflammation, which can be a health risk if the inflammation is not abated by the normal defense system. In the mouth, it can cause gum disease and eventual tooth loss.

"It started with our observation that when the bacterium comes in contact with human epithelial cells, it promotes the induction of these HBD peptides," said Weinberg.

HBDs put up a defense when challenged by oral bacteria and block the invasion of the more than 700 species of bacteria in the mouth from entering the body. Oral bacteria have been linked to pre-term labor, fetal death, heart disease, diabetes and other health conditions.

The researcher and his team have studied the link between the mouth's bacteria and the induction of HBDs for more than a decade, and in a step-by-step process have unraveled the symbiotic relationship between this common oral bacterium and the peptides.

In the process of understanding HBDs and oral bacteria by focusing on F. nucleatum, they discovered FAD-I on the surface of the outer membrane of this bacterium. Even when the outer membrane portion containing FAD-I was separated from the main bacterium, FAD-I continued to induce HBD action in vitro. In addition, when researchers genetically expressed FAD-I in other bacteria that didn't induce HBD expression and release from epithelial cells, the bacteria were then able to induce HBD expression and release, Weinberg explained.

So,the idea is to promote nature's own antibiotics in sites where they would come in contact with FAD-I, Weinberg said.

"The possibility exists that FAD-I can induce defensins in other parts of the body where they are found. Wouldn't it be neat if we could promote the expression of Mother Nature's own antibiotics in vulnerable sites by intentionally challenging the sites with FAD-I and thereby protecting the sites from microbial challenges?"


'/>"/>

Contact: Susan Griffith
susan.griffith@case.edu
216-368-1004
Case Western Reserve University
Source:Eurekalert

Related biology news :

1. Protein switches could turn cancer cells into tiny chemotherapy factories
2. Gene therapy kills breast cancer stem cells, boosts chemotherapy
3. Mothers poor health impairs childrens well-being, not only due to genetics
4. Mothers BMI linked to fatter babies
5. Popular herbal supplements may adversely affect chemotherapy treatment
6. Children of depressed mothers have a different brain
7. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy
8. Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients
9. Your mother was right: Study shows good posture makes you tougher
10. A mothers salt intake could be key to prenatal kidney development
11. B vitamins in mothers diet reduce colorectal cancer risk in offspring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2016)... MOUNTAIN VIEW, Calif. , Dec. 20, 2016  As ... all levels, 23andMe, the leading personal genetics company, recently released ... Only Me . The book focuses on the topics ... the Next Generation Science Standards (NGSS) taught in elementary school ... the second in a series by illustrator Ariana Killoran ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell , ... technology, and STMicroelectronics (NYSE: STM), a global ... electronics applications, announced today the launch of a ... biometric wearables that includes ST,s compact SensorTile ... Benchmark™ biometric sensor system. Together, SensorTile and ...
(Date:12/16/2016)... -- Research and Markets has announced the addition of ... 2021" report to their offering. ... The biometric vehicle access system market, in ... 14.06% from 2016 to 2021. The market is estimated to be ... Million by 2021. The growth of the biometric vehicle access system ...
Breaking Biology News(10 mins):
(Date:1/16/2017)... Ky. , Jan. 16, 2017  Eurofins Genomics ... which will allow more customers to receive their primers ... premium or compromise in quality found with other providers. ... the United States at no additional fee. ... of routine genetic studies, including DNA sequencing, genotyping, site-directed ...
(Date:1/13/2017)... , Jan 13, 2017 Research and Markets ... report to their offering. ... The global biopolymers market to grow at a CAGR of 16.83% during ... and the growth prospects of the global biopolymers market for 2017-2021. To ... sale of sales of biopolymer products. The report also includes a a ...
(Date:1/12/2017)... , ... January 12, 2017 ... ... VTI’S INTERFUSE® IS A SUCCESS , VTI, Vertebral Technologies, Inc., announces the ... InterFuse® laterally expandable device. Since September 2016, VTI (Vertebral Technologies, Inc.) has ...
(Date:1/12/2017)... ... January 12, 2017 , ... After ... Lisa Rosendahl’s doctors gave her only a few months to live. Now a ... that has stabilized Rosendahl’s disease and increased both the quantity and quality of ...
Breaking Biology Technology: